Pitfalls in Conducting Prospective Trials in Stage III Cardiac Amyloidosis - Experience from the REVEAL Study | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Scientific Articles

Pitfalls in Conducting Prospective Trials in Stage III Cardiac Amyloidosis – Experience from the REVEAL Study

key information

source: Amyloid: The International Journal of Experimental and Clinical Investigation

year: 2017

authors: Phillips EH, Nash S, Adedayo T, Whelan CJ, Fontana M, Mahmood S, Lachmann HJ, Gillmore JD, Smith P, Clifton-Hadley L, Hawkins PN, Wechalekar AD

summary/abstract:

Very few prospective clinical trials have been conducted in advanced cardiac AL amyloidosis due to the rarity of the disease and challenging clinical course of the condition. With a median survival of only 7 months, cardiac AL represents a major area of unmet need. 

The introduction of proteasome inhibitors and immunomodulatory agents over the last decade has marked a new era in the treatment of plasma cell dyscrasias. The phase 1 CAN2007 study demonstrated the feasibility of single-agent bortezomib in relapsed/ refractory AL up to a dose of 1.3 mg/m2 twice weekly. The REsponse to VElcade combination chemotherapy in AL amyloidosis (REVEAL) trial was conceived in 2008 to test the efficacy and toxicity of bortezomib-based triplet therapy in AL amyloidosis. Here, we report the course of the REVEAL trial, which illustrates the challenges in conducting trials where high mortality is part of the disease course.

organization: University College London, UK

DOI: 10.1080/13506129.2017.1385453

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close